Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Zoetis Inc Stock Research

ZTS

177.72USD+1.04(+0.59%)Market Closed
Watchlist

Market Summary

USD177.72+1.04
Market Closed
0.59%

ZTS Alerts

  • 3 major insider sales recently.

ZTS Stock Price

ZTS RSI Chart

ZTS Valuation

Market Cap

81.9B

Price/Earnings (Trailing)

37

Price/Sales (Trailing)

9.96

EV/EBITDA

22.65

Price/Free Cashflow

63.72

ZTS Price/Sales (Trailing)

ZTS Profitability

EBT Margin

32.44%

Return on Equity

46.08%

Return on Assets

15.06%

Free Cashflow Yield

1.57%

ZTS Fundamentals

ZTS Revenue

Revenue (TTM)

8.2B

Revenue Y/Y

6.24%

Revenue Q/Q

9%

ZTS Earnings

Earnings (TTM)

2.2B

Earnings Y/Y

26.84%

Earnings Q/Q

21.56%

Price Action

52 Week Range

124.15194.99
(Low)(High)

Last 7 days

-1.1%

Last 30 days

-2.8%

Last 90 days

4.1%

Trailing 12 Months

18.7%

ZTS Financial Health

Current Ratio

3.27

ZTS Investor Care

Dividend Yield

0.82%

Dividend/Share (TTM)

1.45

Buy Backs (1Y)

1.97%

Diluted EPS (TTM)

4.75

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for ZTS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-18
Lagano Roxanne
sold
-165,752
179
-923
executive vice president
2023-09-15
Chen Heidi C.
sold
-1,784,390
180
-9,905
executive vice president
2023-09-01
Lagano Roxanne
sold
-178,111
192
-923
executive vice president
2023-08-22
PECK KRISTIN C
sold
-2,339,560
179
-13,000
chief executive officer
2023-08-22
PECK KRISTIN C
acquired
589,585
45.3527
13,000
chief executive officer
2023-08-09
Polzer Robert J
acquired
169,811
144
1,179
executive vice president
2023-08-09
Polzer Robert J
sold
-223,939
189
-1,179
executive vice president
2023-05-23
PECK KRISTIN C
sold
-2,295,330
176
-13,000
chief executive officer
2023-05-23
PECK KRISTIN C
acquired
543,790
41.83
13,000
chief executive officer
2023-05-19
Norden Gregory
gifted
-
-
-2,659
-

1–10 of 50

Which funds bought or sold ZTS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Halpern Financial, Inc.
new
-
3,272
3,272
-%
2023-09-21
Baystate Wealth Management LLC
added
0.23
2,643
73,976
0.01%
2023-09-20
BARCLAYS PLC
added
106
79,311,000
149,114,000
0.09%
2023-09-18
CAPE ANN SAVINGS BANK
added
2.67
46,634
795,725
0.53%
2023-09-14
IMS Capital Management
added
7.08
44,153
453,429
0.25%
2023-09-13
CGC Financial Services, LLC
new
-
2,928
2,928
-%
2023-09-12
Prosperity Financial Group, Inc.
reduced
-1.63
14,235
812,315
0.72%
2023-09-12
Farther Finance Advisors, LLC
added
3.75
6,530
95,243
0.02%
2023-09-08
TUCKER ASSET MANAGEMENT LLC
unchanged
-
6.00
172
-%
2023-09-07
ST GERMAIN D J CO INC
new
-
5,166
5,166
-%

1–10 of 46

Latest Funds Activity

Are funds buying ZTS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ZTS
No. of Funds

Schedule 13G FIlings of Zoetis

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
7.91%
36,850,763
SC 13G/A
Feb 06, 2023
blackrock inc.
8.6%
40,082,444
SC 13G/A
Feb 03, 2022
blackrock inc.
8.5%
40,315,810
SC 13G/A
Feb 10, 2021
vanguard group inc
7.79%
37,023,889
SC 13G/A
Feb 01, 2021
blackrock inc.
8.6%
40,720,915
SC 13G/A
Feb 12, 2020
vanguard group inc
7.85%
37,400,083
SC 13G/A
Feb 06, 2020
blackrock inc.
8.7%
41,563,670
SC 13G/A

Recent SEC filings of Zoetis

View All Filings
Date Filed Form Type Document
Sep 18, 2023
144
Notice of Insider Sale Intent
Sep 18, 2023
4
Insider Trading
Sep 18, 2023
4
Insider Trading
Sep 15, 2023
144
Notice of Insider Sale Intent
Sep 05, 2023
4
Insider Trading
Sep 01, 2023
144
Notice of Insider Sale Intent
Aug 22, 2023
144
Notice of Insider Sale Intent
Aug 22, 2023
4
Insider Trading
Aug 11, 2023
4
Insider Trading
Aug 09, 2023
144
Notice of Insider Sale Intent

Peers (Alternatives to Zoetis)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
496.9B
29.5B
-0.25% 77.82%
76.47
16.84
1.53% 14.16%
416.4B
97.8B
-3.60% -2.56%
31.9
4.26
2.29% -28.92%
272.8B
58.3B
-3.97% 23.63%
17.88
4.63
2.00% -81.24%
186.2B
77.9B
-9.35% -24.54%
8.67
2.39
-23.04% -26.74%
150.1B
45.2B
-4.70% -15.70%
23.72
3.25
-4.15% 20.34%
MID-CAP
6.5B
-
1.99% 679.20%
-74.1
4.1K
-86.94% 71.24%
4.4B
4.6B
-14.16% -15.49%
-64.33
0.94
6.60% 42.04%
SMALL-CAP
1.7B
627.1M
-7.75% -5.51%
-1.16
2.69
-0.20% -204.67%
1.5B
634.0M
-9.02% -13.66%
35.75
2.44
0.62% -24.59%
851.8M
244.3M
-1.80% 10.68%
4.32
3.49
-39.50% -4.99%
830.8M
109.5M
28.99% -23.78%
-5.79
7.59
-2.66% -32.13%
519.0M
453.3M
141.77% -66.80%
-0.42
1.14
-16.04% 55.90%
464.2M
31.2M
-4.93% -49.81%
-4.41
14.9
407.54% -26.47%
252.8M
54.6M
-17.99% -39.70%
-2.79
4.63
9.39% -179.16%
-
2.2B
- -
-
-
-22.39% 63.59%

Zoetis News

MarketBeat
HM Payson & Co. Trims Stock Holdings in Zoetis Inc. (NYSE:ZTS).
MarketBeat,
52 minutes ago
Investor's Business Daily
AbbVie Stock Shows Rising Relative Strength Rating.
Investor's Business Daily,
4 days ago
Barron's
Investor's Business Daily

Returns for ZTS

Cumulative Returns on ZTS

19.8%


10-Year Cumulative Returns

20.1%


7-Year Cumulative Returns

15.1%


5-Year Cumulative Returns

3.9%


3-Year Cumulative Returns

Risks for ZTS

What is the probability of a big loss on ZTS?

49.2%


Probability that Zoetis stock will be more than 20% underwater in next one year

36.5%


Probability that Zoetis stock will be more than 30% underwater in next one year.

4.2%


Probability that Zoetis stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ZTS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Zoetis was unfortunately bought at previous high price.

Drawdowns

Financials for Zoetis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue1.6%8,2228,0948,0808,0077,9957,8917,7767,6167,4127,0126,6756,5426,3406,3396,2606,1506,0465,9145,8255,7215,588
  S&GA Expenses1.3%2,0762,0492,0092,0882,0912,0572,0011,9281,8481,7461,7261,6781,6451,6581,6381,5861,5621,5151,4841,4251,386
EBITDA-100.0%-3,3283,3423,2463,2363,2013,1603,0703,0152,8612,6682,6832,6042,5612,436------
EBITDA Margin-100.0%-0.41*0.41*0.41*-0.41*0.41*0.40*0.41*0.41*0.40*0.41*0.41*0.40*0.39*0.39*-----
Interest Expenses2.2%236231221213216220224228234235231229223220223226224215206197186
Earnings Before Taxes7.7%2,8282,6262,6562,5702,5622,5282,4882,4022,3402,1861,9962,0131,9441,9171,8011,7821,6721,6541,6901,7021,697
EBT Margin-100.0%-0.32*0.33*0.32*-0.32*0.32*0.32*0.32*0.31*0.30*0.31*0.31*0.30*0.29*0.29*-----
Net Income6.9%2,2132,0712,1142,0672,0902,0732,0371,9821,9091,7741,6381,6631,6171,6111,5001,4611,3751,3881,4281,1641,115
Net Income Margin-100.0%-0.26*0.26*0.26*-0.26*0.26*0.26*0.26*0.25*0.25*0.25*0.26*0.25*0.24*0.24*-----
Free Cashflow-100.0%-1,4581,3261,2671,4291,6071,7361,7911,7021,6821,6731,5231,4561,3231,335------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets0.0%13,74913,75414,92513,67413,77013,86013,90013,70514,06913,79613,60913,72513,06911,52811,54511,27210,98610,88310,80010,4598,603
  Current Assets-1.4%6,1836,2697,5066,5516,6516,8376,9306,6827,0486,7946,6116,7576,2854,7724,7484,6184,4844,3794,3994,0764,239
    Cash Equivalents-18.6%1,7172,1093,5812,5072,6523,1353,4853,2743,6583,6023,6043,6543,3531,9511,9341,8151,7551,7281,6021,2861,558
  Inventory5.4%2,7012,5632,3452,3032,2052,0571,9231,8751,8021,7001,6281,6261,5841,4811,4101,4391,4041,3611,3911,4411,420
  Net PPE3.4%3,0112,9132,7532,6232,5592,4872,4222,3382,2862,2272,2022,0992,0111,9771,9401,8131,7391,6831,6581,5561,470
  Goodwill-0.9%2,7142,7382,7462,6922,7202,6852,6822,7032,7182,7072,6942,6902,6292,5832,5922,5502,5052,5222,5192,5371,514
Liabilities-1.5%9,1289,26310,5229,0129,1909,2029,3569,0249,7179,7049,83610,11810,0828,7758,8378,5948,5758,5668,5928,3416,621
  Current Liabilities-7.6%1,7691,9153,1672,8803,0513,0341,7971,4712,0912,0662,1702,4001,8111,7211,8061,0521,0751,0821,2231,003967
  Short Term Borrowings-33.3%2.003.002.003.002.00---4.004.004.001.001.00-----9.00--
    LT Debt, Current---1,3501,3501,3501,350--6006006001,100500-500------
    LT Debt, Non Current-0.1%6,5556,5596,5525,2105,2215,2286,5926,5926,5926,5876,5956,5957,1945,9635,9476,4476,4466,4446,4436,4414,955
Shareholder's Equity3.0%4,6254,4914,4054,6634,5804,6584,5444,6814,3524,0923,7733,6072,9872,7532,7082,6782,4112,3172,1852,1181,982
  Retained Earnings5.5%9,5439,0458,6688,5338,0047,6287,1867,0446,4926,0995,6595,5265,0484,7644,4274,2173,7883,4953,2703,0672,722
  Additional Paid-In Capital1.8%1,0981,0791,0881,0731,0591,0461,0681,0561,0441,0301,0651,0401,0301,0171,0441,0311,0191,0081,0261,0101,001
Accumulated Depreciation3.1%2,4472,3742,2972,2322,1932,1412,0722,1132,0642,0121,9521,8941,8181,7691,7371,7251,6851,6421,5991,5591,522
Shares Outstanding-0.4%461462464466470472473474475476475476475476476478479480480482484
Minority Interest-33.3%-4.00-3.00-2.00-1.00--1.002.002.003.004.005.005.00-------12.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-7.1%1,9992,1521,9121,8501,9772,1222,2132,2522,1612,1182,1261,9901,9341,8141,7951,7971,8411,7901,7901,8141,703
  Share Based Compensation3.6%57.0055.0062.0060.0060.0061.0058.0057.0056.0056.0059.0062.0064.0065.0067.0068.0052.0037.0053.0024.0027.00
Cashflow From Investing12.5%-858-981-883-587-577-513-458-493-553-578-572-608-643-538-504-365-2,220-2,237-2,259-2,239-303
Cashflow From Financing5.4%-2,045-2,161-904-1,998-2,388-2,068-1,862-2,145-1,319112123470331-1,036-951-898597552533-237-544
  Buy Backs-8.4%1,3891,5161,5941,3871,208923743545347181250426576726626600593658698673655

ZTS Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Millions, $ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Revenue$ 2,180$ 2,052$ 4,180$ 4,038
Costs and expenses:    
Cost of sales6076251,1951,194
Selling, general and administrative expenses5565291,061994
Research and development expenses146135288257
Amortization of intangible assets37377478
Restructuring charges and certain acquisition-related costs81293
Interest expense, net of capitalized interest5853121106
Other (income)/deductions—net(104)2(157)9
Income before provision for taxes on income8726701,569[1]1,397[1]
Provision for taxes on income202141348274
Net income before allocation to noncontrolling interests6705291,2211,123
Less: Net loss attributable to noncontrolling interests(1)0(2)(1)
Net income attributable to Zoetis Inc.$ 671$ 529$ 1,223$ 1,124
Earnings per share attributable to Zoetis Inc. stockholders:    
Basic (in dollars per share)$ 1.45$ 1.13$ 2.64$ 2.39
Diluted (in dollars per share)$ 1.45$ 1.12$ 2.64$ 2.38
Weighted-average common shares outstanding:    
Basic (in shares)461.9470.0462.7471.1
Diluted (in shares)462.9471.5463.8472.8
Dividends paid per common share (in dollars per share)$ 0.375$ 0.325$ 0.750$ 0.650
[1]Defined as income before provision for taxes on income.

ZTS Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Assets  
Cash and cash equivalents[1]$ 1,717$ 3,581
Accounts receivable, less allowance for doubtful accounts of $20 in 2023 and $19 in 20221,3221,215
Inventories2,7012,345
Other current assets443365
Total current assets6,1837,506
Property, plant and equipment, less accumulated depreciation of $2,447 in 2023 and $2,297 in 20223,0112,753
Operating lease right of use assets224220
Goodwill2,7142,746
Identifiable intangible assets, less accumulated amortization1,2521,380
Noncurrent deferred tax assets192173
Other noncurrent assets173147
Total assets13,74914,925
Liabilities and Equity  
Short-term borrowings22
Current portion of long-term debt01,350
Accounts payable464405
Dividends payable173174
Accrued expenses689682
Accrued compensation and related items247300
Income taxes payable87157
Other current liabilities10797
Total current liabilities1,7693,167
Long-term debt, net of discount and issuance costs6,5556,552
Noncurrent deferred tax liabilities121142
Operating lease liabilities188186
Other taxes payable278258
Other noncurrent liabilities217217
Total liabilities9,12810,522
Commitments and contingencies (Note 15)
Stockholders' equity:  
Common stock, $0.01 par value: 6,000,000,000 authorized; 501,891,243 and 501,891,243 shares issued; 460,750,652 and 463,808,059 shares outstanding at June 30, 2023, and December 31, 2022, respectively55
Treasury stock, at cost, 41,140,591 and 38,083,184 shares of common stock at June 30, 2023 and December 31, 2022, respectively(5,126)(4,539)
Additional paid-in capital1,0981,088
Retained earnings9,5438,668
Accumulated other comprehensive loss(895)(817)
Total Zoetis Inc. equity4,6254,405
Noncontrolling interests(4)(2)
Total equity4,6214,403
Total liabilities and equity$ 13,749$ 14,925
[1]As of June 30, 2023 and December 31, 2022, includes $3 million and $4 million of restricted cash, respectively.
Kristin C. Peck
12100
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.